Asia-Pacific induced pluripotent stem cells (iPSCs) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.2% in the forecast period of 2022 to 2029 and is expected to reach USD 460.45 million by 2029.
The induced pluripotent stem cells are a type of cells derived from the adult somatic tissues and re-programmed with set of genes and factors to gain pluripotent nature. Certain genes and elements are added to attain definite properties of embryonic stem cells. The induced pluripotent cells being nearly identical to cell donor aid in disease modeling. Retroviruses are commonly used as vectors to reprogram induced pluripotent stem cells. Main applications of induced pluripotent stem cells are in disease modelling, drug discovery and development, toxicity studies, and gene therapies. They are widely used in treatments for cardiovascular diseases, diabetes mellitus and various types of cancer. Human induced pluripotent stem cells shows the relevant properties of disease as it carries the specific genotype of the disease, thereby enables novel therapeutic options in patient specific way.
Increasing adoption of stem cell therapy, growing biotechnology sector with better investment, and rising prevalence of chronic diseases acts as driver for the induced pluripotent stem cells (iPSCs) market. The other factors which are anticipated to propel the growth of the Asia-Pacific induced pluripotent stem cells (iPSCs) market include the Wide range of clinical applications of induced pluripotent stem cells and emerging technological advancements of iPSCs.
However, the factors such as the high cost associated with stem cell therapies, availability of alternatives for tumor treatment are hampering the growth of the Asia-Pacific induced pluripotent stem cells (iPSCs) market. On the other hand, the rising number of pipeline products, increased interest of personalized medicine and surge in healthcare expenditure act as an opportunity for the growth of the Asia-Pacific induced pluripotent stem cells (iPSCs) market. The stringent rules and regulations and Genomic instability of IPSC is the key market challenge faced in the Asia-Pacific induced pluripotent stem cells (iPSCs) market.
The induced pluripotent stem cells (iPSCs) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the induced pluripotent stem cells (iPSCs) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Browse Detailed Summary of Research Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-induced-pluripotent-stem-cells-market
Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size
The induced pluripotent stem cells (iPSCs) market is segmented on basis of cell source, type, product, applications, end users, and distribution channel The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Asia-Pacific induced pluripotent stem cells (iPSCs) market is categorized into six notable segments based on the cell source, type, product, applications, end users, and distribution channel.
- On the basis of cell source, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. In 2022, skin cells segment is expected to dominate the market due to easy availability of skin cells.
- On the basis of type, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. In 2022, human IPSCs segment is expected to dominate the market as they are majorly used for therapeutic applications
- On the basis of product, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables kits and services. In 2022, consumables kits segment is expected to dominate the market as they are used in toxicity testing and drug discoveries.
- On the basis of application, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modeling, stem cell banking, 3D bioprinting, and others. In 2022, drug discovery and development segment is expected to dominate the market as stem cells are gaining more attention novel drug inventions.
- On the basis of end-users, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into biotechnology pharmaceutical companies, research laboratories, diagnostic laboratories, and others. In 2022, the biotechnology pharmaceutical companies segment is expected to dominate the market due to high investment by companies to expand their facilities.
- On the basis of distribution channel, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. In 2022, direct tender segment is expected to dominate the market as they provide products with high quality.
Induced Pluripotent Stem Cells (iPSCs) Market Country Level Analysis
The induced pluripotent stem cells (iPSCs) market is analyzed, and market size information is provided by the country, cell source, type, product, applications, end users, and distribution channel as referenced above.
The countries covered in the induced pluripotent stem cells (iPSCs) market report are China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, and rest of Asia-Pacific.
Consumables Kits segment in China of Asia Pacific region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of stem cell technology. The consumables kits segment in Japan is second dominating the market owing to increasing cases of chronic diseases and high adoption of stem cell sources for better therapies. India is third in leading the growth of the Asia-Pacific market, and the consumables kits segment is dominating in this country due to increasing number of biotechnology centers and research activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Induced Pluripotent Stem Cells (iPSCs) Treatment is Boosting the Market Growth of Induced Pluripotent Stem Cells (iPSCs) Market.
The induced pluripotent stem cells (iPSCs) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Induced Pluripotent Stem Cells (iPSCs) Market Share Analysis
Induced pluripotent stem cells (iPSCs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induced pluripotent stem cells (iPSCs) market.
The major companies which are dealing in the induced pluripotent stem cells (iPSCs) Thermo Fisher Scientific Inc., FUJIFILM Corporation, Hopstem Biotechnology LLC., Takara Bio Inc., Lonza., R D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Merck KGaA and among others domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Top Trending’s Reports:-
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability levels and advanced approaches. We are committed to uncovering the best consumer prospects and fostering useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expanded its reach by opening a new office in the Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475